Denmark · Delayed Price · Currency is DKK Genmab Statistics
Total Valuation
Genmab has a market cap or net worth of DKK 103.79 billion. The enterprise value is 128.59 billion.
| Market Cap | 103.79B |
| Enterprise Value | 128.59B |
Important Dates
The last earnings date was Thursday, May 7, 2026.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Genmab has 61.39 million shares outstanding. The number of shares has decreased by -2.55% in one year.
| Current Share Class | 61.39M |
| Shares Outstanding | 61.39M |
| Shares Change (YoY) | -2.55% |
| Shares Change (QoQ) | +1.17% |
| Owned by Insiders (%) | 1.18% |
| Owned by Institutions (%) | 61.76% |
| Float | 60.65M |
Valuation Ratios
The trailing PE ratio is 19.89 and the forward PE ratio is 20.48. Genmab's PEG ratio is 1.08.
| PE Ratio | 19.89 |
| Forward PE | 20.48 |
| PS Ratio | 4.10 |
| PB Ratio | 2.82 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 18.36 |
| P/OCF Ratio | 17.75 |
| PEG Ratio | 1.08 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.73, with an EV/FCF ratio of 22.75.
| EV / Earnings | 24.16 |
| EV / Sales | 5.09 |
| EV / EBITDA | 14.73 |
| EV / EBIT | 15.41 |
| EV / FCF | 22.75 |
Financial Position
The company has a current ratio of 2.18, with a Debt / Equity ratio of 0.94.
| Current Ratio | 2.18 |
| Quick Ratio | 2.17 |
| Debt / Equity | 0.94 |
| Debt / EBITDA | 3.97 |
| Debt / FCF | 6.14 |
| Interest Coverage | 7.66 |
Financial Efficiency
Return on equity (ROE) is 14.96% and return on invested capital (ROIC) is 10.72%.
| Return on Equity (ROE) | 14.96% |
| Return on Assets (ROA) | 8.48% |
| Return on Invested Capital (ROIC) | 10.72% |
| Return on Capital Employed (ROCE) | 11.49% |
| Weighted Average Cost of Capital (WACC) | 6.68% |
| Revenue Per Employee | 8.19M |
| Profits Per Employee | 1.72M |
| Employee Count | 3,088 |
| Asset Turnover | 0.41 |
| Inventory Turnover | 15.82 |
Taxes
In the past 12 months, Genmab has paid 1.38 billion in taxes.
| Income Tax | 1.38B |
| Effective Tax Rate | 20.60% |
Stock Price Statistics
The stock price has increased by +27.97% in the last 52 weeks. The beta is 0.70, so Genmab's price volatility has been lower than the market average.
| Beta (5Y) | 0.70 |
| 52-Week Price Change | +27.97% |
| 50-Day Moving Average | 1,728.31 |
| 200-Day Moving Average | 1,845.99 |
| Relative Strength Index (RSI) | 45.84 |
| Average Volume (20 Days) | 150,149 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Genmab had revenue of DKK 25.29 billion and earned 5.32 billion in profits. Earnings per share was 84.98.
| Revenue | 25.29B |
| Gross Profit | 23.60B |
| Operating Income | 8.34B |
| Pretax Income | 6.70B |
| Net Income | 5.32B |
| EBITDA | 8.62B |
| EBIT | 8.34B |
| Earnings Per Share (EPS) | 84.98 |
Balance Sheet
The company has 9.89 billion in cash and 34.69 billion in debt, with a net cash position of -24.80 billion or -403.96 per share.
| Cash & Cash Equivalents | 9.89B |
| Total Debt | 34.69B |
| Net Cash | -24.80B |
| Net Cash Per Share | -403.96 |
| Equity (Book Value) | 36.83B |
| Book Value Per Share | 600.02 |
| Working Capital | 9.04B |
Cash Flow
In the last 12 months, operating cash flow was 5.85 billion and capital expenditures -194.47 million, giving a free cash flow of 5.65 billion.
| Operating Cash Flow | 5.85B |
| Capital Expenditures | -194.47M |
| Depreciation & Amortization | 275.71M |
| Net Borrowing | 34.75B |
| Free Cash Flow | 5.65B |
| FCF Per Share | 92.07 |
Margins
Gross margin is 93.31%, with operating and profit margins of 32.99% and 21.05%.
| Gross Margin | 93.31% |
| Operating Margin | 32.99% |
| Pretax Margin | 26.51% |
| Profit Margin | 21.05% |
| EBITDA Margin | 34.09% |
| EBIT Margin | 32.99% |
| FCF Margin | 22.35% |
Dividends & Yields
Genmab does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 2.55% |
| Shareholder Yield | 2.55% |
| Earnings Yield | 5.13% |
| FCF Yield | 5.45% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Genmab has an Altman Z-Score of 2.72 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.72 |
| Piotroski F-Score | 4 |